Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04094610
Recruitment Status : Recruiting
First Posted : September 19, 2019
Last Update Posted : February 12, 2020
Sponsor:
Information provided by (Responsible Party):
Turning Point Therapeutics, Inc.

Brief Summary:
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D).

Condition or disease Intervention/treatment Phase
Locally Advanced Solid Tumors Metastatic Solid Tumors Lymphoma Primary CNS Tumors Drug: Oral repotrectinib (TPX-0005) Phase 1 Phase 2

Detailed Description:

Enrollment of subjects into Phase 1 will proceed concurrently by age as follows:

• Subjects 4 to <12 years old will initially be enrolled in the Phase 1 part to determine the pediatric RP2D for this age group.

Phase 1:

Approximately 12 pediatric subjects with locally advanced or metastatic solid tumors, including a primary central nervous system (CNS) tumor, or anaplastic large cell lymphoma (ALCL), with disease progression or who are non-responsive or intolerant to available therapies and for which no standard or available curative therapy exists.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
Estimated Study Start Date : February 2020
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2023


Arm Intervention/treatment
Experimental: Repotrectinib (TPX-0005)

Phase 1

Oral repotrectinib (TPX-0005):

Safety and tolerability at different dose levels

Drug: Oral repotrectinib (TPX-0005)
Oral repotrectinib (TPX-0005)
Other Names:
  • Oral repotrectinib (TPX-0005) capsules
  • repotrectinib




Primary Outcome Measures :
  1. Dose limiting toxicities (DLTs) (Phase 1) [ Time Frame: Within 28 days of the first repotrectinib dose ]
    Define the dose limiting toxicities (DLTs) (Phase 1)

  2. Pediatric Recommended Phase 2 Dose (RP2D) (Phase 1) [ Time Frame: Within 28 days of the last patient dosed in escalation ]
    To determine the pediatric RP2D (Phase 1)


Secondary Outcome Measures :
  1. Overall Response Rate (ORR) (Phase 1) [ Time Frame: Approximately three years ]
    To determine the overall response rate (ORR) by Blinded Independent Central Review (BICR) (Phase 1)

  2. Clinical Benefit Rate (CBR) (Phase 1) [ Time Frame: Approximately three years ]
    To determine the CBR of repotrectinib (TPX-0005) (Phase 1)

  3. Time to response (TTR) (Phase 1) [ Time Frame: Approximately three years ]
    To determine the TTR of reprotrectinib (TPX-005) (Phase 1)

  4. Duration of response (DOR) (Phase 1) [ Time Frame: Approximately three years ]
    To determine the DOR of repotrectinib (TPX-0005) (Phase 1)

  5. Intracranial objective response rate (IC-ORR) (Phase 1) [ Time Frame: Approximately three years ]
    To determine the IC-ORR of repotrectinib (TPX-005) (Phase 1)

  6. Maximum concentration of repotrectinib in plasma (Cmax) [ Time Frame: Pre-dose and up to 24 hours post-dose on Day 1 and Day 15 in Cycle 1 (each cycle is 28 days) ]
    To determine the Cmax

  7. Area under the concentration versus time curve of repotrectinib in plasma (AUC) [ Time Frame: Pre-dose and up to 24 hours post-dose on Day 1 and Day 15 in Cycle 1 (each cycle is 28 days) ]
    To determine the AUC



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   4 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Documented genetic ALK, ROS1, or NTRK1-3 alteration (point mutation, fusion, amplification) as identified by local testing in a Clinical Laboratory Improvement Amendments (CLIA) laboratory in the US or equivalently accredited diagnostic lab outside the United States (US) is required.
  2. Age 4 to <12 years.
  3. Capability to swallow capsules intact (without chewing, crushing, or opening).
  4. Prior cytotoxic chemotherapy is allowed.
  5. Prior immunotherapy is allowed.
  6. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.
  7. All subjects must have measurable disease by RECIST v1.1 or Response Assessment in Neuro-Oncology Criteria (RANO) criteria at time of enrollment.
  8. Subjects with a primary CNS tumor or CNS metastases must be neurologically stable on a stable or decreasing dose of steroids for at least 14 days prior to enrollment.
  9. Subjects must have a Lansky (< 16 years) score of at least 50.
  10. Life expectancy greater than or equal to 12 weeks.
  11. Adequate hematologic, renal and hepatic function.

Key Exclusion Criteria:

  1. Subjects with neuroblastoma with only bone marrow disease evaluable by bone marrow aspiration only.
  2. Major surgery within 14 days (2 weeks) of start of repotrectinib treatment. Central venous access (Broviac, Mediport, etc.) placement does not meet criteria for major surgery.
  3. Known active infections (bacterial, fungal, viral including HIV positivity).
  4. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.
  5. Any of the following cardiac criteria:

    • Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTc) > 470 msec obtained from three ECGs, using the screening clinic ECG machine-derived QTc value
    • Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec)
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval
  6. Peripheral neuropathy of CTCAE ≥grade 2.
  7. Subjects being treated with or anticipating the need for treatment with strong CYP3A4 inhibitors or inducers.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04094610


Contacts
Layout table for location contacts
Contact: Zachary Zimmerman, M.D. (858) 276-0005 clinical@tptherapeutics.com

Locations
Layout table for location information
United States, Florida
Arnold Palmer Hospital for Children Recruiting
Orlando, Florida, United States, 32806
Principal Investigator: Ana Aguilar-Bonilla, MD         
United States, Massachusetts
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Principal Investigator: Steven G. DuBois, MD         
United States, New Jersey
Rutgers Cancer Institute of New Jersey Recruiting
New Brunswick, New Jersey, United States, 08901
Principal Investigator: Scott Moerdler, MD         
United States, Texas
The University of Texas Southwestern Medical Center, Children's Medical Center of Dallas Recruiting
Dallas, Texas, United States, 75235
Principal Investigator: Theodore Laetsch, MD         
Sponsors and Collaborators
Turning Point Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Zachary Zimmerman, M.D. Turning Point Therapeutics

Layout table for additonal information
Responsible Party: Turning Point Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04094610    
Other Study ID Numbers: TPX-0005-07
First Posted: September 19, 2019    Key Record Dates
Last Update Posted: February 12, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There are no plans to share individual participant data with other researchers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Turning Point Therapeutics, Inc.:
Primary CNS tumor
metastatic solid tumor
advanced solid tumor
solitary fibrous tumor
inflammatory myofibroblastic tumor
ALK
ROS1
NTRK1-3
anaplastic large cell lymphoma
sarcoma
infantile fibrosarcoma
glioblastoma
soft tissue schwannoma
glioma
pediatric
Additional relevant MeSH terms:
Layout table for MeSH terms
Central Nervous System Neoplasms
Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases